Paper32754259
EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H and 10 others. Theranostics, 2020. Cited by 73 papers, by iCite.
Cite this record
ConductScience Library. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer. Papers, record 32754259. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32754259
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Enhancer of Zeste Homolog 2 Protein | Major topic |
| MicroRNAs | Major topic |
| Protein-Lysine 6-Oxidase | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Cell Movement | |
| Cell Proliferation | |
| Disease Progression | |
| Epigenesis, Genetic | |
| Female | |
| Gene Expression Regulation, Neoplastic | |
| Humans | |
| MCF-7 Cells | |
| Mice | |
| Neoplasm Metastasis | |
| Neoplasm Transplantation | |
| Tumor Microenvironment |
Source PubMed
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31367244 | A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep. | Theranostics | 2019 | https://conductscience.org/library/papers/31367244 | PubMed |
| 2 | 21115743 | Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. | Mol Cancer Res | 2010 | https://conductscience.org/library/papers/21115743 | PubMed |
| 3 | 22810810 | The rationale for targeting the LOX family in cancer. | Nat Rev Cancer | 2012 | https://conductscience.org/library/papers/22810810 | PubMed |
| 4 | 26290412 | Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis. | Sci Transl Med | 2015 | https://conductscience.org/library/papers/26290412 | PubMed |
| 5 | 26068592 | Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. | Cell Death Differ | 2016 | https://conductscience.org/library/papers/26068592 | PubMed |
| 6 | 11292829 | Molecular cloning and biological activity of a novel lysyl oxidase-related gene expressed in cartilage. | J Biol Chem | 2001 | https://conductscience.org/library/papers/11292829 | PubMed |
| 7 | 26756583 | Lysyl oxidase like-4 monoclonal antibody demonstrates therapeutic effect against head and neck squamous cell carcinoma cells and xenografts. | Int J Cancer | 2016 | https://conductscience.org/library/papers/26756583 | PubMed |
| 8 | 30064438 | The long non-coding RNA CYTOR drives colorectal cancer progression by interacting with NCL and Sam68. | Mol Cancer | 2018 | https://conductscience.org/library/papers/30064438 | PubMed |
| 9 | 30704479 | Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis. | Mol Cancer | 2019 | https://conductscience.org/library/papers/30704479 | PubMed |
| 10 | 26845405 | Targeting EZH2 in cancer. | Nat Med | 2016 | https://conductscience.org/library/papers/26845405 | PubMed |
| 11 | 28060764 | LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/28060764 | PubMed |
| 12 | 26171207 | miR-29b is an indicator of prognosis in breast cancer patients. | Mol Clin Oncol | 2015 | https://conductscience.org/library/papers/26171207 | PubMed |
| 13 | 24607405 | Metastatic stem cells: sources, niches, and vital pathways. | Cell Stem Cell | 2014 | https://conductscience.org/library/papers/24607405 | PubMed |
| 14 | 31410199 | Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer. | Theranostics | 2019 | https://conductscience.org/library/papers/31410199 | PubMed |
| 15 | 25028505 | Molecular pathways: connecting fibrosis and solid tumor metastasis. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/25028505 | PubMed |
| 16 | 27179746 | Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. | Pharmacol Ther | 2016 | https://conductscience.org/library/papers/27179746 | PubMed |
| 17 | 23539298 | EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis. | Breast Cancer Res Treat | 2013 | https://conductscience.org/library/papers/23539298 | PubMed |
| 18 | 18039110 | Tumor stroma and regulation of cancer development. | Annu Rev Pathol | 2006 | https://conductscience.org/library/papers/18039110 | PubMed |
| 19 | 30993701 | Downregulation of lysyl oxidase-like 4 LOXL4 by miR-135a-5p promotes lung cancer progression in vitro and in vivo. | J Cell Physiol | 2019 | https://conductscience.org/library/papers/30993701 | PubMed |
| 20 | 23079660 | Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. | Cancer Cell | 2012 | https://conductscience.org/library/papers/23079660 | PubMed |
Cited by52
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 73 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42749970 | LOXL4: a key regulatory factor at the intersection of fibrosis and tumor progression. | Hum Cell | 2026 | https://conductscience.org/library/papers/42749970 | PubMed |
| 42348113 | Identification of Ferroptosis-related Genes Associated with the Prognosis of Hepatocellular Carcinoma. | Cell Biochem Biophys | 2026 | https://conductscience.org/library/papers/42348113 | PubMed |
| 39960560 | Enhancer zeste homolog 2 (EZH2) targeting by small interfering RNA (siRNA); recent advances and prospect. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/39960560 | PubMed |
| 39247609 | Lysyl Oxidase (LOX) Family Proteins: Key Players in Breast Cancer Occurrence and Progression. | J Cancer | 2024 | https://conductscience.org/library/papers/39247609 | PubMed |
| 38774662 | H3K27Me3 abundance increases fibrogenesis during endothelial-to-mesenchymal transition via the silencing of microRNA-29c. | Front Cardiovasc Med | 2024 | https://conductscience.org/library/papers/38774662 | PubMed |
| 38737700 | The dual role of LOXL4 in the pathogenesis and development of human malignant tumors: a narrative review. | Transl Cancer Res | 2024 | https://conductscience.org/library/papers/38737700 | PubMed |
| 38534385 | EZH2-Myc Hallmark in Oncovirus/Cytomegalovirus Infections and Cytomegalovirus' Resemblance to Oncoviruses. | Cells | 2024 | https://conductscience.org/library/papers/38534385 | PubMed |
| 38339377 | Decoding the Tumour Microenvironment: Molecular Players, Pathways, and Therapeutic Targets in Cancer Treatment. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38339377 | PubMed |
| 38333212 | Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures. | Front Immunol | 2024 | https://conductscience.org/library/papers/38333212 | PubMed |
| 38246995 | Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy. | J Transl Med | 2024 | https://conductscience.org/library/papers/38246995 | PubMed |
| 38008711 | EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/38008711 | PubMed |
| 37958880 | Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37958880 | PubMed |
| 37941557 | Circulating tumor biomarkers in early-stage breast cancer: characteristics, detection, and clinical developments. | Front Oncol | 2023 | https://conductscience.org/library/papers/37941557 | PubMed |
| 37904207 | miR-3195 suppresses the malignant progression of osteosarcoma cells via targeting SOX4. | J Orthop Surg Res | 2023 | https://conductscience.org/library/papers/37904207 | PubMed |
| 37814029 | The possibilities of LOXL4 as a prognostic marker for carcinomas. | Amino Acids | 2023 | https://conductscience.org/library/papers/37814029 | PubMed |
| 37803297 | Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner. | BMC Cancer | 2023 | https://conductscience.org/library/papers/37803297 | PubMed |
| 37626362 | Analysis on EZH2: mechanism identification of related CeRNA and its immunoassay in hepatocellular carcinoma. | BMC Med Genomics | 2023 | https://conductscience.org/library/papers/37626362 | PubMed |
| 37373139 | Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37373139 | PubMed |
| 37217462 | Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37217462 | PubMed |
| 37197500 | miR-183-5p regulates ECM and EMT to promote non-small cell lung cancer progression by targeting LOXL4. | J Thorac Dis | 2023 | https://conductscience.org/library/papers/37197500 | PubMed |
Genes25
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32754259
GET https://conductscience.org/api/papers/v1/32754259/references?page=2